Acumen Pharmaceuticals pays off K2 HealthVentures loan, cuts 52 jobs
The company terminated its 2023 term loan with a $23.3 million payoff and moved forward with a workforce reduction tied to halting its sabirnetug program.
Acumen Pharmaceuticals disclosed in an 8-K dated November 1, 2026 that it has closed out its debt facility with K2 HealthVentures LLC and formally started a restructuring. The company had entered a Loan and Security Agreement with K2 HealthVentures on November 10, 2023, providing for a term loan facility of up to $50.0 million, of which $30.0 million was drawn in the first tranche at signing.1 That loan carried interest at the greater of 9.65% annually or prime plus 1.15%, was set to mature November 1, 2027, and included a final payment fee of $1.6 million due at repayment.1
According to the filing, Acumen notified the lender on November 3, 2026 that it intended to voluntarily repay the full balance using cash on hand, putting the total payoff at approximately $23.3 million.1 That sum covered the remaining principal, accrued interest, the final payment fee and certain expenses owed to the lender.1 Once K2 HealthVentures received the funds on November 5, 2026, the loan agreement and related documents were terminated, the lender's commitments and conversion right ended, and all liens tied to the loan were released.1
The filing also details cost estimates tied to Acumen's program wind-down. As disclosed in an October 30, 2026 8-K, the company said it would stop developing sabirnetug, including the open-label extension of the ALTITUDE-AD trial, and would review strategic alternatives for its Enhanced Brain Delivery (EBD) program.1 On November 1, 2026 the board approved cash conservation steps including cutting 52 full-time positions, about 90% of its workforce, with the reduction starting November 2, 2026 and most roles ending that month, though a few continue into early 2027.1
Acumen estimates the restructuring will cost about $7.75 million in cash severance and related expenses, with most charges booked in the fourth quarter of 2026 and first quarter of 2027, and the process largely finished by early 2027.1 The company said it expects further costs from evaluating strategic options, including advisory and outplacement services, but has not yet been able to estimate those amounts and will amend the 8-K once it can.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.